How I navigated the Society Of Neuro Oncology 2022 proceedings
The abstract submission window for the annual meeting closed on a Tuesday in early spring. I had about 48 hours to finalize a poster on IDH-mutant glioma progression patterns after my lab finished the sequencing run. This happened more times than I care to count, but the 2022 edition had some quirks that caught me off guard. Most people treat this conference like just another checkbox on their academic calendar. The actual value sits in the cross-talk between neuro-oncologists and radiation oncologists during the satellite sessions. I spent three years watching the same group of researchers reference each other's work without citing properly. The 2022 meeting finally produced a structured framework for how to handle that gap. The registration portal ran on a completely different platform that year. Instead of the usual simple web form, they switched to a system that required ORCID verification before you could even access the abstract submission page. This added about twenty minutes to the initial setup but eliminated roughly half of the problematic submissions we used to see. I recommend building your account at least a week before the deadline if you have institutional SSO issues.
Practical steps for getting your work presented
First, the abstract format shifted from 300 words to 400 words with a mandatory structured section for methodology. This caught several investigators off guard. I spent an evening reformatting three abstracts that would have been rejected otherwise. The key insight nobody mentioned was that the word count applied to the entire document including tables and figure legends when uploaded to the portal. For download purposes, the proceedings didn't publish as a traditional bound volume. Instead, they uploaded everything to a secure portal accessible through your conference credential. I've seen people waste hours trying to find PDF downloads that simply don't exist. The files are organized by session type, not by topic. A clinical trial presentation about temozolomide resistance might appear under "Therapeutic Advances" while a basic science study on the same mechanism sits in "Molecular Mechanisms." The poster session layout deserves special mention. They abandoned the traditional board numbering system and used a geographic mapping approach tied to room capacity. I spent twenty minutes walking across the convention floor looking for a poster labeled "B-14" before realizing that designation no longer existed. The new system assigned codes based on department and initial letter. It took me until the second day to internalize this.
What actually works from the 2022 methodology sessions
The most useful framework I encountered dealt with biomarker validation for recurrent glioblastoma. Several groups presented conflicting data on whether circulating tumor DNA could reliably replace repeat biopsy for treatment decisions. The panel didn't reach consensus, which is probably the most honest outcome possible given the current state of the field. One practical takeaway involves the standardized reporting checklist they introduced. Instead of the usual free-form abstract structure, presenters had to address specific elements: sample size justification, statistical power assumptions, and confounding variable identification. This forced clearer thinking during the submission process. I found myself catching methodological flaws in my own work that I had previously overlooked. The networking component worked differently this year. They implemented a scheduled meeting system through the conference app. This eliminated the traditional hallway conversations where most collaborations actually form. I personally found the structured scheduling helpful for maximizing limited time, but several senior investigators complained about losing spontaneous interactions. If you're attending primarily for collaboration opportunities, arrive with specific people you want to discuss projects with.
Get the Full Details
Common mistakes I watched others make
The citation requirements for referenced work caused confusion. The portal accepted citations in Vancouver format but the displayed abstract showed them in AMA style. I watched at least five people submit with incorrectly formatted references that looked wrong in the final program. Double-check how your citations appear after upload, not just how they look in your document. Travel logistics deserve attention. The hotel block booking system released rooms in phases rather than all at once. I saw several colleagues attempt to book accommodations three days before departure only to find nothing available within walking distance. The official rate remained available at the primary hotel but room availability became severely limited. Another issue involved the presentation technology. They switched from traditional projectors to large-format LED displays for all oral presentations. Several speakers prepared materials assuming standard 4:3 aspect ratio and encountered formatting problems. Prepare everything in 16:9 and test the rendering on your laptop before arriving.
The workaround for problematic abstract submissions
I encountered a technical issue where the portal rejected a perfectly valid PDF containing Chinese characters in the affiliation text. The error message indicated a font encoding problem, but the file had been generated through standard LaTeX compilation. The solution involved embedding the problematic text as plain ASCII in a separate field rather than attempting Unicode support in the main document. This took three attempts to discover through conversation with the technical support staff on site. For image uploads accompanying abstracts, the system imposed a strict 5MB limit per file. Several groups submitted high-resolution microscopy images that exceeded this threshold. The workaround involved compressing through standard image editing software while maintaining sufficient resolution for detail identification. I found that reducing DPI from 300 to 200 while preserving pixel dimensions worked adequately for presentation purposes.
Assessing the actual outcomes and limitations
The meeting produced several position statements that may influence how institutions approach clinical trials in neuro-oncology. The most significant involved standardization of response assessment criteria for immune-related adverse events in patients receiving checkpoint inhibitors for primary brain tumors. This addresses a genuine gap that has persisted for years. However, the proceedings lacked substantial data on treatment optimization for rare molecular subtypes. Nearly all presented research focused on IDH-mutant or EGFRvIII-positive populations. Patients with less common alterations simply weren't represented in the abstract program. This reflects a broader limitation in how clinical trial recruitment operates rather than a failure of the meeting organization itself. The virtual attendance component operated through a dedicated platform separate from the in-person experience. I observed significant delays between live presentation and digital streaming, ranging from fifteen to forty-five seconds depending on bandwidth allocation. This created awkward pauses during Q&A sessions where remote participants couldn't interact in real time.
Certificate and continuing education credit processing remains inefficient. The system claimed to issue credentials within 72 hours but several attendees I spoke with received them weeks later. If you need documentation for institutional requirements, request alternative proof of attendance before departure rather than relying on the automated system. The social programming proved adequate but unremarkable. The welcome reception featured standard networking opportunities without the structured introduction format that some conferences implement. I found the actual value in the smaller satellite workshops rather than the main plenary sessions. Budget your time accordingly if you prioritize hands-on learning over general overview presentations.
